Celcuity Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BAKER BROS. ADVISORS LP, was filed 10 Sept 2025.
Who traded when
BuySaleSince the insiders bought
- +45.3%Entry US$57.43 · Close at T+365 US$83.45
- +52.9%Entry US$10.23 · Close at T+365 US$15.64
- +42.6%Entry US$10.38 · Close at T+365 US$14.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 250 shares@ US$7.600.0001% mcap1.7% of flowCommon StockSEC:0001775749-26-000004:0
- 893 shares0Common StockSEC:0001202335-26-000007:0
- 80,000 shares0Common StockSEC:0000940454-26-000002:0
- 20,000 shares0Common StockSEC:0001716041-26-000004:0
- 16,000 shares0Common StockSEC:0001716043-26-000002:0
- ▼
Same trade as the filing by Baker Brothers Life Sciences, L.P., counted once
291M USD33SEC2,838,632 shares@ US$102.507.43% mcap91.4% of flowCommon StockSEC:0001193125-26-306299:1 - 261,368 shares@ US$102.500.68% mcap8.4% of flowCommon StockSEC:0001193125-26-306299:0
- 261,368 shares@ US$102.500.68% mcap100.0% of flowCommon StockSEC144:0001104659-26-083659
- 2,838,632 shares@ US$102.507.43% mcap100.0% of flowCommon StockSEC144:0001104659-26-083657
- 1,530 shares0Common StockSEC:0001296457-26-000008:0
- 1,530 shares0Common StockSEC:0001775749-26-000002:0
- 1,530 shares0Common StockSEC:0001688319-26-000008:0
- 1,530 shares0Common StockSEC:0001213869-26-000007:0
- 1,530 shares0Common StockSEC:0001809717-26-000008:0
- 1,530 shares0Common StockSEC:0001829248-26-000002:0
- 1,000 shares@ US$9.890.0002% mcap100.0% of flowCommon StockSEC:0001716041-26-000002:0
- 10,000 shares0Common StockSEC:0001213869-26-000005:0
- 3,000 shares@ US$5.103.3% of flowCommon StockSEC:0001688319-26-000002:0
- 2,325 shares@ US$110.105754.6% of flowCommon StockSEC:0001688319-26-000002:1
- 675 shares@ US$110.826816.0% of flowCommon StockSEC:0001688319-26-000002:2
- 215 shares0Common StockSEC:0001809717-26-000006:0
- 20,000 shares@ US$120.026956.0% of flowCommon StockSEC:0001296457-26-000003:0
- 19,975 shares0Common StockSEC:0001213869-26-000002:0
- 1,490 shares@ US$105.3411.7% of flowCommon StockSEC:0001688319-25-000013:1
- 1,510 shares@ US$106.0411.9% of flowCommon StockSEC:0001688319-25-000013:2
25 of 128 declarations
About Celcuity Inc.
Baker Bros. Advisors LP, a holder of more than 10% of the capital of Celcuity Inc., appears on both sides: a purchase of EUR 7,238,152 on September 8, 2025, then EUR 667,620 the same day, and the largest sale in the record, EUR 23,521,814 on July 14, 2026. From November 22 to December 9, 2022, two insiders bought EUR 1,467,720, including Brian F. Sullivan (Chief Executive Officer), EUR 1,420,497 on December 9, 2022.
The 14 purchases total EUR 10,330,696, median EUR 110,040, against 49 sales worth EUR 32,400,447, median EUR 5,276: 22% of open-market trades are purchases. David Dalvey (Director) sold EUR 2,129,910 on July 28, 2025 and EUR 2,021,253 on January 27, 2026; Dalvey signs 18 filings, 15 of them sales. Richard E. Buller (Director) signs 50, 33 of them sales, and Richard Nigon (Director) 13, seven of them purchases.
Read moreShow less
The US healthcare and pharma company, listed on Nasdaq, valued at USD 2.8 billion and 10.2% held by its insiders, saw its annual volume rise from 16 in 2022 to 36 in 2025. Over twelve months, 33 filings, nine of them sales and no purchase. For 14 purchases, the median 90-day result is 26.3%, with 71% positive (past results on record, not a forecast).
